CYPHERPUNK TECHNOLOGIES INC.
CYPH · XNASCIK 1509745fmd_0E3PVAJB0HYK60D0TGEA416A0JManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2016 to Jun 30, 2026, 42 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | 2 | 2 | – | – | – | – |
| Research and development | 23 | 23 | 22 | 24 | 20 | 32 | 45 | 73 | 57 | 26 |
| Total operating expenses | 27 | 32 | 31 | 33 | 30 | 43 | 57 | 87 | 70 | 41 |
| Operating income | (27) | (32) | (31) | (33) | (29) | (41) | (57) | (87) | (70) | (41) |
| Interest expense | – | 1 | 0 | 0 | 0 | 0 | 0 | – | – | 0 |
| Other non-operating income (expense) | (0) | (0) | – | – | – | – | – | – | – | – |
| Income before taxes | (26) | (30) | (23) | (33) | (28) | (41) | (54) | (81) | (67) | 10 |
| Income tax expense | – | (0) | 0 | (0) | (0) | (0) | 0 | – | 1 | 5 |
| Net income from continuing operations | – | (30) | (23) | (33) | (28) | (41) | (55) | – | (68) | 5 |
| Net income | (26) | (30) | (23) | (33) | (28) | (41) | (55) | (81) | (68) | 5 |
| Net income to common shareholders | – | (30) | (23) | (33) | (38) | (41) | (55) | (81) | (68) | 5 |